AIDS

Skip Navigation LinksHome > May 15, 2010 - Volume 24 - Issue 8 > Lower atovaquone/proguanil concentrations in patients taking...
AIDS:
doi: 10.1097/QAD.0b013e3283389129
Research Letters

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

Van Luin, Matthijsa,b,c; Van der Ende, Marchina Ed; Richter, Clemense; Visser, Mirjamb; Faraj, Diarif; Van der Ven, Andrec,g; Gelinck, Luch,i; Kroon, Franki; Wit, Ferdinand Wj; Van Schaik, Ron HNk; Kuks, Paul FMb; Burger, David Ma,c

Collapse Box

Abstract

HIV-infected travellers frequently use atovaquone/proguanil as malaria prophylaxis. We compared atovaquone/proguanil pharmacokinetics between healthy volunteers and HIV-infected patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. The geometric mean ratio (95% confidence interval) area under the curve (AUC)0→t for atovaquone relative to the healthy volunteers was 0.25 (0.16–0.38), 0.26 (0.17–0.41) and 0.54 (0.35–0.83) for patients on efavirenz, lopinavir/ritonavir and atazanavir/ritonavir, respectively. Proguanil plasma concentrations were also significantly lower (38–43%). Physicians should be alert for atovaquone/proguanil prophylaxis failures in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Level Metrics